Neurogene (NASDAQ:NGNE) CFO Christine Mikail Cvijic Sells 4,200 Shares

Neurogene Inc. (NASDAQ:NGNE) CFO Christine Mikail Cvijic sold 4,200 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total value of $151,746.00. Following the sale, the chief financial officer directly owned 84,040 shares of the company’s stock, valued at $3,036,365.20. This represents a 4.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Christine Mikail Cvijic also recently made the following trade(s):

• On Monday, July 6th, Christine Mikail Cvijic sold 600 shares of Neurogene stock. The shares were sold at an average price of $36.02, for a total transaction of $21,612.00.
• On Thursday, July 2nd, Christine Mikail Cvijic sold 4,061 shares of Neurogene stock. The stock was sold at an average price of $34.82, for a total transaction of $141,404.02.
• On Wednesday, July 1st, Christine Mikail Cvijic sold 739 shares of Neurogene stock. The stock was sold at an average price of $34.06, for a total transaction of $25,170.34.
• On Wednesday, May 6th, Christine Mikail Cvijic sold 9,600 shares of Neurogene stock. The stock was sold at an average price of $31.25, for a total transaction of $300,000.00.

Neurogene Price Performance

Shares of NASDAQ NGNE opened at $36.80 on Wednesday. Neurogene Inc. has a fifty-two week low of $15.93 and a fifty-two week high of $37.27. The firm has a market capitalization of $581.44 million, a P/E ratio of -8.09 and a beta of 1.68. The company’s 50 day simple moving average is $29.70 and its 200 day simple moving average is $23.57.

Neurogene (NASDAQ:NGNE) last released its earnings results on Tuesday, May 12th. The company reported ($1.39) EPS for the quarter, missing analysts’ consensus estimates of ($1.30) by ($0.09). Sell-side analysts expect that Neurogene Inc. will post -5.63 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. UBS Group set a $70.00 price target on Neurogene in a research note on Wednesday, June 3rd. Rodman & Renshaw started coverage on shares of Neurogene in a report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 price objective for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research note on Tuesday, April 21st. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Neurogene in a research note on Tuesday, June 9th. Finally, Canaccord Genuity Group cut their target price on shares of Neurogene to $180.00 and set a “buy” rating on the stock in a report on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $84.83.

Institutional Investors Weigh In On Neurogene

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets lifted its holdings in shares of Neurogene by 89.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock valued at $36,000 after purchasing an additional 978 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in Neurogene during the 4th quarter worth approximately $66,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Neurogene by 17.9% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after buying an additional 1,059 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in Neurogene in the fourth quarter valued at approximately $165,000. Finally, Bridgeway Capital Management LLC bought a new position in Neurogene in the third quarter valued at approximately $187,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.